Skip to main content

Table 3 Associations with time to major adverse cardiovascular events and all-cause mortality

From: Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study

  MACE ACM
HR (95% CI) p value HR (95% CI) p value
Univariate analysis
 Sex (F vs M) 1.49 (1.02–2.18) 0.038 1.40 (0.88–2.24) 0.16
 Age 1.05 (1.04–1.07) 2.0 × 10−9 1.09 (1.06–1.11) 1.9 × 10−12
 All multimorbidity 2.69 (1.73–4.20) 1.2 × 10−5 2.75 (1.56–4.84) 4.8 × 10−4
 Number of drugs 1.15 (1.10–1.21) 2.0 × 10−8 1.14 (1.08–1.21) 3.0 × 10−6
 Number of all interactions 1.16 (0.995–1.34) 0.058 1.01 (0.83–1.23) 0.93
 Number of substantial interactions 1.23 (0.997–1.51) 0.053 1.11 (0.84–1.46) 0.47
Multivariable analysis
 Age 1.05 (1.03–1.07) 8.9 × 10−7 1.08 (1.06–1.11) 1.9 × 10−12
 All multimorbidity 1.76 (1.10–2.82) 0.019
 Number of drugs 1.10 (1.04–1.16) 1.2 × 10−3 1.12 (1.05–1.19) 4.0 × 10−4
  1. ACM all-cause mortality, CI confidence interval, HR hazard ratio, MACE major adverse cardiovascular events
  2. All types of interaction (drug-drug, drug-gene, drug-drug-gene, and drug-gene-gene) were counted to determine numbers of all and numbers of predicted substantial interactions per patient